Loading...

Home
ETF
SRPT

SRPT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

SRPT News

Roche Initiates New Phase 3 Trial for Elevidys Gene Therapy

4d agoseekingalpha

Capricor's Former Executive Considered for FDA Biologics Chief

6d agostocktwits

SAREPTA THERAPEUTICS INC: RBC Increases Target Price from $18 to $19

Apr 07 2026moomoo

SAREPTA THERAPEUTICS, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $12 TO $14

Mar 26 2026moomoo

SAREPTA THERAPEUTICS INC: WEDBUSH INCREASES TARGET PRICE FROM $29 TO $35

Mar 26 2026moomoo

SAREPTA THERAPEUTICS INC: CITIGROUP INCREASES TARGET PRICE FROM $9 TO $13

Mar 26 2026moomoo

SAREPTA THERAPEUTICS INC: PIPER SANDLER INCREASES TARGET PRICE FROM $16 TO $23

Mar 26 2026moomoo

Sarepta's Promising Data Sparks Market Optimism

Mar 25 2026stocktwits

SRPT Stock Sees Largest Daily Increase in Almost 8 Years Following Rare Muscle Disorders Study, Yet Wall Street Remains Skeptical

Mar 25 2026stocktwits

Sarepta Reports Promising Clinical Results for siRNA Programs

Mar 25 2026NASDAQ.COM

Precious Metals Stocks Surge, Led by Aura Minerals

Mar 25 2026NASDAQ.COM

Sarepta Shares Jump 30% Following Gene Therapy Trials, But Safety Concerns Persist.

Mar 25 2026Barron's

Sarepta Shares Jump 29% Following Gene Therapy Trials, But Safety Concerns Persist.

Mar 25 2026Barron's

Sarepta Therapeutics Shares Surge 25% on Promising Clinical Trial Data

Mar 25 2026seekingalpha

Sarepta Reports Promising Results in Genetic Muscle Disease Trials

Mar 25 2026stocktwits

SRPT Shares Surge Following Positive Initial Results for RNA Treatments Aimed at Rare Muscle Disorders

Mar 25 2026stocktwits